LABORATORIO FARMAC.ERFO (RK7) - Total Assets
Based on the latest financial reports, LABORATORIO FARMAC.ERFO (RK7) holds total assets worth €10.52 Million EUR (≈ $12.30 Million USD) as of June 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See RK7 net assets for net asset value and shareholders' equity analysis.
LABORATORIO FARMAC.ERFO - Total Assets Trend (2021–2023)
This chart illustrates how LABORATORIO FARMAC.ERFO's total assets have evolved over time, based on quarterly financial data.
LABORATORIO FARMAC.ERFO - Asset Composition Analysis
Current Asset Composition (December 2023)
LABORATORIO FARMAC.ERFO's total assets of €10.52 Million consist of 0.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.3% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.57 Million | 35.2% |
| Goodwill | €3.67K | 0.0% |
Asset Composition Trend (2021–2023)
This chart illustrates how LABORATORIO FARMAC.ERFO's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RK7 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LABORATORIO FARMAC.ERFO's current assets represent 0.0% of total assets in 2023, a decrease from 22.6% in 2021.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2023, up from 5.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 35.0% of total assets, an increase from 34.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 35.2% of total assets.
LABORATORIO FARMAC.ERFO Competitors by Total Assets
Key competitors of LABORATORIO FARMAC.ERFO based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Saputo Inc
TO:SAP
|
Canada | CA$13.32 Billion |
|
COFCO Tunhe Sugar Co Ltd
SHG:600737
|
China | CN¥22.01 Billion |
|
Lotus Health Group Co
SHG:600186
|
China | CN¥3.27 Billion |
|
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.
SHG:605016
|
China | CN¥2.80 Billion |
|
SDIC Zhonglu Fruit Juice Co Ltd
SHG:600962
|
China | CN¥2.60 Billion |
|
Xiangpiaopiao Food Co Ltd
SHG:603711
|
China | CN¥4.72 Billion |
|
Kri-Kri Milk Industry S.A
AT:KRI
|
Greece | €219.80 Million |
|
Youyou Foods Co Ltd
SHG:603697
|
China | CN¥2.32 Billion |
LABORATORIO FARMAC.ERFO - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.61 | - | - |
| Quick Ratio | 1.16 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | €1.52 Million | - | - |
LABORATORIO FARMAC.ERFO - Advanced Valuation Insights
This section examines the relationship between LABORATORIO FARMAC.ERFO's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.03 |
| Latest Market Cap to Assets Ratio | 0.94 |
| Asset Growth Rate (YoY) | -3.7% |
| Total Assets | €10.15 Million |
| Market Capitalization | $9.56 Million USD |
Valuation Analysis
Near Book Valuation: The market values LABORATORIO FARMAC.ERFO's assets close to their book value (0.94x), suggesting investors view the company's assets at approximately fair value.
Slight Asset Contraction: LABORATORIO FARMAC.ERFO's assets decreased by 3.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for LABORATORIO FARMAC.ERFO (2021–2023)
The table below shows the annual total assets of LABORATORIO FARMAC.ERFO from 2021 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €10.15 Million ≈ $11.86 Million |
-3.68% |
| 2022-12-31 | €10.53 Million ≈ $12.32 Million |
+51.90% |
| 2021-12-31 | €6.93 Million ≈ $8.11 Million |
-- |
About LABORATORIO FARMAC.ERFO
Laboratorio Farmaceutico Erfo S.p.A. engages in the formulation and production of food supplements in Italy. It produces various types of pharmaceutical forms, such as bottles, single-dose vials and bottles, capsules, tablets, and sachets under the Diètnatural and Gianopharma brands, as well as private label brands. The company offers custom formula creation, regulatory advice, graphics, and pack… Read more